Loading company
Kiniksa Pharmaceuticals International, plc
KNSA · Nasdaq · ·
Next earnings: October 27, 2026
$75.77-0.5%Sep 29 close
- 1M
- -3.0%
- 6M
- +65.8%
- 1Y
- +95.1%
- 5Y
- +526.2%
KNSA · Nasdaq · ·
Next earnings: October 27, 2026
$75.77-0.5%Sep 29 close
Kiniksa Pharmaceuticals International, plc is scheduled to report next on October 27, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $214.3M | $137.8M | +55.51% |
| Profit | $22.6M | $8.5M | +164.57% |
| Profit per share | $0.27 | $0.11 | +145.45% |
| Free Cash Flow | $50M | $22.2M | +125.14% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“In the second quarter, Kiniksa continued to drive growth in new and repeat prescribers of ARCALYST in recurrent pericarditis, which led to a meaningful increase in patients on therapy. As a result, we have raised our 2026 ARCALYST net sales guidance to between $980 and $995 million,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Kiniksa Pharmaceuticals International, plc’s Item 2.02 8-K filed July 28, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Kiniksa Pharmaceuticals International, plc has no earnings call transcript available.